DSwiss, Inc (DQWS) Fair Value & Analysis
Consumer Defensive · US · Market cap $8.7M
Fair value as of: Jun 23, 2026
Analysis
DSwiss, Inc (DQWS) currently trades at $0.0420, while our model-based Fair Value estimate is $0.0200 — implying the stock looks roughly 52.4% overvalued today. We read business quality at 95/100 (high quality), in the Consumer Defensive sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
About the company
DSwiss, Inc., a biotech nutraceutical company, provides healthcare, skincare, and personal care products in Malaysia, Singapore, Indonesia, Australia, Hong Kong, Taiwan, Macau, and China. It supplies health and beauty products, including weight management beverages, anti-aging creams, and immune system enhancers. The company also provides private label manufacturing services for nutraceutical and skincare/personal care ODM/OEM products; pet wellness supplements; and pet-care products, as well as medical consumable supplies, such as disposable stretcher cover and bedsheet, masks, body infrared thermometers, sanitizer, protective goggles, surgical gloves, isolation suit, industrial disinfectant, and protection surgical and medical gown. In addition, it offers OEM/ODM/OBM services, such as DSwiss quantum magnetic analyzer and DNA genotyping services; Eyecare; and biotechnology research channel services. DSwiss, Inc. was incorporated in 2015 and is headquartered in Kuala Lumpur, Malaysia.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is DSwiss, Inc (DQWS) undervalued?
What is the fair value of DQWS?
What is the quality score of DQWS?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.